Peak Bio Inc. is a clinical-stage biopharmaceutical company, which engages in the commercialization of therapeutics that aim to address the medical need of patients with inflammatory, rare and specialty diseases, and cancer. The company is headquartered in Pleasanton, California. The company went IPO on 2021-01-28. The firm's pipeline includes an antibody-drug-conjugate (ADC) platform that includes novel toxins and linkers coupled with important cancer antibody targets and a Phase 2-ready neutrophil elastase inhibitor for alpha1 anti-trypsin deficiency disorder (AATD). Its clinical stage, phase 2 ready asset, PHP-303 (its lead product candidate), is being investigated for the treatment of AATD, a rare genetic disorder and exploring opportunities with PHP-303 for the treatment of acute respiratory distress syndrome (ARDS). PHP- 303 is an oral, once daily, potent, selective small molecule inhibitor of neutrophil elastase (NE) designed to inhibit the bioactive form of NE. Its proprietary toxin, PH-1 or Thailanstatin (a spliceosome modulator) is being used to generate its first pipeline of novel ADC product candidates.

Industry: Biological Products, (No Diagnostic Substances) Peers: RenovaCare, Inc. Aptevo Therapeutics Inc Aridis Pharmaceuticals, Inc. Imunon Inc Corbus Pharmaceuticals Holdings Inc Cyclo Therapeutics, Inc. Plus Therapeutics Inc YIELD10 BIOSCIENCE, INC. Minerva Neurosciences Inc